Literature DB >> 21034422

Receptor mediated tumor targeting: an emerging approach for cancer therapy.

Chandana Mohanty1, Manasi Das, Jagat R Kanwar, Sanjeeb K Sahoo.   

Abstract

Receptor-mediated tumor targeting has received major attention in the field of cancer drug delivery in the past few years. Receptors, as molecular target has opened new opportunities for cellular or intracellular targeting of drug loaded delivery systems conjugated with targeting moieties i.e. ligand. This receptor mediated targeting of cancer drug through nano carrier systems to cancerous tissue offer protection and improves the pharmacokinetics of various drugs and help to overcome the systemic toxicity and adverse effects that result from the non-selective nature of most current cancer therapeutic agents. The article reviews the scope of receptor mediated targeting of anticancer drug loaded in various nanocarriers and also summarize recent perspective and challenges in the field of nanocarrier-aided drug delivery and drug targeting for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21034422     DOI: 10.2174/156720111793663606

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  19 in total

1.  PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy.

Authors:  Fereydoon Abedi-Gaballu; Gholamreza Dehghan; Maryam Ghaffari; Reza Yekta; Soheil Abbaspour-Ravasjani; Behzad Baradaran; Jafar Ezzati Nazhad Dolatabadi; Michael R Hamblin
Journal:  Appl Mater Today       Date:  2018-05-29

2.  LHRH-targeted nanogels as a delivery system for cisplatin to ovarian cancer.

Authors:  Natalia V Nukolova; Hardeep S Oberoi; Yi Zhao; Vladimir P Chekhonin; Alexander V Kabanov; Tatiana K Bronich
Journal:  Mol Pharm       Date:  2013-08-30       Impact factor: 4.939

3.  Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein.

Authors:  Naohiko Koshikawa; Daisuke Hoshino; Hiroaki Taniguchi; Tomoko Minegishi; Taizo Tomari; Sung-Ouk Nam; Mikiko Aoki; Takayuki Sueta; Takashi Nakagawa; Shingo Miyamoto; Kazuki Nabeshima; Alissa M Weaver; Motoharu Seiki
Journal:  Cancer Res       Date:  2015-06-30       Impact factor: 12.701

Review 4.  Bioengineering strategies for designing targeted cancer therapies.

Authors:  Angela A Alexander-Bryant; Wendy S Vanden Berg-Foels; Xuejun Wen
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

5.  In vitro evaluation of the efficacy of liposomal and pegylated liposomal hydroxyurea.

Authors:  Seyed Ebrahim Alavi; Maedeh Koohi Moftakhari Esfahani; Soheil Ghassemi; Azim Akbarzadeh; Gholamhossein Hassanshahi
Journal:  Indian J Clin Biochem       Date:  2013-03-26

6.  Boronate-mediated biologic delivery.

Authors:  Gregory A Ellis; Michael J Palte; Ronald T Raines
Journal:  J Am Chem Soc       Date:  2012-02-13       Impact factor: 15.419

7.  Dual-targeting pro-apoptotic peptide for programmed cancer cell death via specific mitochondria damage.

Authors:  Wei-Hai Chen; Xiao-Ding Xu; Guo-Feng Luo; Hui-Zhen Jia; Qi Lei; Si-Xue Cheng; Ren-Xi Zhuo; Xian-Zheng Zhang
Journal:  Sci Rep       Date:  2013-12-16       Impact factor: 4.379

8.  Design of multifunctional magnetic iron oxide nanoparticles/mitoxantrone-loaded liposomes for both magnetic resonance imaging and targeted cancer therapy.

Authors:  Yingna He; Linhua Zhang; Dunwan Zhu; Cunxian Song
Journal:  Int J Nanomedicine       Date:  2014-08-22

9.  Newcastle Disease Virus Hemagglutinin Neuraminidase as a Potential Cancer Targeting Agent.

Authors:  Ali Baradaran; Khatijah Yusoff; Norazizah Shafee; Raha Abdul Rahim
Journal:  J Cancer       Date:  2016-01-29       Impact factor: 4.207

10.  Mechanisms of Drug Resistance and Use of Nanoparticle Delivery to Overcome Resistance in Breast Cancers.

Authors:  Huseyin Beyaz; Hasan Uludag; Doga Kavaz; Nahit Rizaner
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.